Discover
REVB
Revelation Biosciences, Inc.
0.76
2 x 0.58
2 x 1.00
bid
ask
-
0.02
2.58%
2 @ 04:00 PM
0.75 -0.01 (1.29%)
| Ytd | -76.25% | |
| 1y | -87.08% |
0.75
day range
0.82
0.75
52 week range
5.88
| Open | 0.77 | Prev Close | 0.78 | Low | 0.75 | High | 0.82 | Mkt Cap | 3.03M |
| Vol | 24.79K | Avg Vol | 39.50K | EPS | 4.60 | P/E | 0.17 | Forward P/E | -0.13 |
| Beta | -0.07 | Short Ratio | 0.11 | Inst. Own | 8.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.98 | 200-d Avg | 1.40 | 1yr Est | 12.75 |
| Income Statement | |||
| Operating Expenses | 3.66M | ||
| Research and Development Expense | 1.92M | ||
| Selling, General and Administrative Expense | 1.74M | ||
| Operating Income | -3.66M | ||
| Net Income | -3.32M | ||
| Net Income Common Stock | -3.32M | ||
| Net Income Common Stock (USD) | -3.32M | ||
| Consolidated Income | -3.32M | ||
| Earnings per Basic Share | -0.87 | ||
| Earnings per Basic Share (USD) | -0.87 | ||
| Earnings per Diluted Share | -0.87 | ||
| Earning Before Interest & Taxes (EBIT) | -3.32M | ||
| Earning Before Interest & Taxes (USD) | -3.32M | ||
| Weighted Average Shares | 3.83M | ||
| Weighted Average Shares Diluted | 3.83M | ||
| Balance Sheet | |||
| Cash and Equivalents | 11.48M | ||
| Cash and Equivalents (USD) | 11.48M | ||
| Current Assets | 11.68M | ||
| Property, Plant & Equipment Net | 782.48K | ||
| Total Assets | 12.50M | ||
| Debt Current | 189.37K | ||
| Total Debt | 739.92K | ||
| Current Liabilities | 1.88M | ||
| Debt Non-Current | 550.55K | ||
| Total Liabilities | 2.43M | ||
| Accumulated Retained Earnings (Deficit) | -55.75M | ||
| Shareholders Equity | 10.07M | ||
| Shareholders Equity (USD) | 10.07M | ||
| Assets Non-Current | 813.42K | ||
| Total Debt (USD) | 739.92K | ||
| Liabilities Non-Current | 550.55K | ||
| Trade and Non-Trade Payables | 931.09K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 64.46K | ||
| Net Cash Flow from Financing | -33.80K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.63M | ||
| Capital Expenditure | -39.63K | ||
| Net Cash Flow from Investing | -39.63K | ||
| Net Cash Flow from Operations | -2.56M | ||
| Share Based Compensation | 401.42K | ||